Acute Leukemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) Test
Short Name: Acute Leukemia Mini Panel
Also known as: Leukemia Gene Rearrangement Panel, AML Molecular Marker Panel, Acute Leukemia Translocation Panel, Hematologic Malignancy Gene Panel, Leukemia RT-PCR Panel
Acute Leukemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) Test test available at DNA Labs India for ₹9,750. Uses Real-Time Polymerase Chain Reaction (RT-PCR), Reverse Transcription PCR on Bone Marrow Aspirate / Peripheral Blood samples. Results in Results are typically available within 5–6 business days after sample collection. Reports can be accessed through the DNA Labs India online portal, received via email, or delivered through WhatsApp.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr Pasupathy Arumugam
Consultant Pathologist · Reg: 21521
Last reviewed: September 7, 2026
Overview
The Acute Leukemia Mini Panel is performed to detect specific gene rearrangements that are characteristic of acute leukemia subtypes. This test serves multiple purposes: it aids in the accurate classification of leukemia according to the World Health Organization (WHO) criteria, helps determine patient prognosis, guides the selection of targeted therapies, and may be used for monitoring treatment response and minimal residual disease (MRD). It is an essential component of the molecular diagnostic workup for patients with suspected or newly diagnosed acute leukemia.
- Test Code
- 2954
- CPT Code
- 81315, 81317, 81319, 81321, 81323, 81342, 81359
- ICD Code
- C92.0, C91.0
- Price
- ₹9,750
- Sample Type
- Bone Marrow Aspirate / Peripheral Blood
- Result Time
- Results are typically available within 5–6 business days after sample collection. Reports can be accessed through the DNA Labs India online portal, received via email, or delivered through WhatsApp.
- Fasting Required
- No
- Method
- Real-Time Polymerase Chain Reaction (RT-PCR), Reverse Transcription PCR
Sample Collection
A doctor's prescription is required for this test. No fasting is necessary. Inform your physician about any current medications, ongoing treatments, or recent chemotherapy sessions. For the most accurate results, the sample should ideally be collected before the initiation of chemotherapy. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
Method: Venipuncture (peripheral blood) or Bone Marrow Aspiration from posterior iliac crest
Laboratory Analysis
A peripheral blood sample (approximately 2 ml) will be drawn from a vein in your arm using standard venipuncture, or a bone marrow aspirate will be collected from the posterior iliac crest under local anesthesia. The blood draw takes approximately 5–10 minutes, while bone marrow aspiration may take 15–30 minutes. The sample is immediately placed in an EDTA vacutainer and transported with a cool pack.
Report Delivery
Apply gentle pressure to the puncture site for a few minutes. Mild bruising or soreness may occur at the collection site. You may resume normal activities immediately after a blood draw. If a bone marrow aspirate was performed, avoid strenuous activity for 24 hours and follow your physician's post-procedure instructions. Results will be available in 5–6 business days.
Timeline: Results are typically available within 5–6 business days after sample collection. Reports can be accessed through the DNA Labs India online portal, received via email, or delivered through WhatsApp.
Patient Instructions
About This Test
Who Should Get This Test
The Acute Leukemia Mini Panel is performed to detect specific gene rearrangements that are characteristic of acute leukemia subtypes. This test serves multiple purposes: it aids in the accurate classification of leukemia according to the World Health Organization (WHO) criteria, helps determine patient prognosis, guides the selection of targeted therapies, and may be used for monitoring treatment response and minimal residual disease (MRD). It is an essential component of the molecular diagnostic workup for patients with suspected or newly diagnosed acute leukemia.
How to Prepare
- Collect bone marrow aspirate or peripheral blood in an EDTA vacutainer (2 ml)
- Label the sample clearly with patient name, date of birth, sample type, and date of collection
- Transport the sample immediately to the laboratory with a cool pack at 2–8°C
- Avoid hemolyzed, clotted, or insufficient volume samples
- Ensure the sample reaches the laboratory within 24 hours of collection for optimal RNA preservation
- Include the doctor's prescription and completed requisition form with the sample
Doctor's Notes
Reviewed by Dr Pasupathy Arumugam — MBBS, MD (Pathology) · Reg. No. 21521
"The Acute Leukemia Mini Panel is an invaluable tool in the initial diagnostic workup of patients with suspected acute leukemia. Detection of specific gene rearrangements not only aids in accurate classification according to the WHO system but also has direct therapeutic implications. For instance, identifying PML/RARA allows for the immediate initiation of differentiation therapy with all-trans retinoic acid (ATRA), which has dramatically improved outcomes in acute promyelocytic leukemia. Similarly, BCR/ABL detection guides the use of tyrosine kinase inhibitors. I recommend this panel for all newly diagnosed acute leukemia patients as part of a comprehensive molecular diagnostic workup alongside morphology, immunophenotyping, and conventional cytogenetics."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Clotted sample
- Hemolyzed sample
- Insufficient sample volume (less than 1 ml)
- Sample received without proper labeling or identification
- Sample received without doctor's prescription
- Sample transported without appropriate temperature control or received beyond 24 hours post-collection
- Leaked or damaged vacutainer
Understanding Your Results
No detectable gene rearrangements among the seven tested markers. This does not rule out acute leukemia. Further evaluation with comprehensive molecular testing, conventional cytogenetics, and clinical correlation is recommended.
Detection of the AML1/ETO fusion gene is associated with AML with maturation (FAB M2 subtype). Generally confers a favorable prognosis. Patients typically benefit from intensive chemotherapy regimens including high-dose cytarabine.
Detection of the CBFB/MYH11 fusion gene indicates AML with abnormal eosinophils (FAB M4eo subtype). Generally associated with a favorable prognosis. Patients typically respond well to intensive chemotherapy with high-dose cytarabine.
Detection of the PML/RARA fusion gene confirms acute promyelocytic leukemia (APL, FAB M3). This is a medical emergency due to the risk of disseminated intravascular coagulation (DIC). Immediate treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is required. Favorable prognosis with appropriate therapy.
Detection of the BCR/ABL fusion gene (Philadelphia chromosome) may indicate chronic myeloid leukemia in blast crisis or Philadelphia chromosome-positive acute leukemia (AML or ALL). Targeted therapy with tyrosine kinase inhibitors (TKIs) such as imatinib is indicated. Prognosis depends on the leukemia subtype and response to therapy.
Detection of the ETV6/RUNX1 fusion gene is the most common genetic abnormality in childhood B-cell ALL, found in approximately 25% of pediatric B-ALL cases. Associated with an excellent prognosis with standard multi-agent chemotherapy protocols.
Detection of MLL gene rearrangement at chromosome 11q23 is associated with various leukemia subtypes including AML, ALL, and mixed-phenotype acute leukemia. Generally confers a poor prognosis, particularly in infants and adults. Allogeneic hematopoietic stem cell transplantation may be considered in first complete remission.
Detection of the TCF3/PBX1 fusion gene is associated with pre-B cell ALL. Confers an intermediate prognosis. Intensified chemotherapy regimens and close monitoring for CNS involvement may be recommended.
Consult your hematologist-oncologist if you experience persistent fatigue, unexplained weight loss, frequent infections, easy bruising or bleeding, bone or joint pain, swollen lymph nodes, or night sweats. If your Acute Leukemia Mini Panel results are positive for any gene rearrangement, seek immediate consultation with a hematologist-oncologist for further evaluation, risk stratification, and treatment planning. Early consultation is critical for optimal outcomes in acute leukemia. If all markers are negative but clinical suspicion remains high, discuss additional testing options with your physician.
Limitations
- ⚠This panel tests for only 7 specific gene rearrangements and may not detect all genetic abnormalities associated with acute leukemia
- ⚠A negative result does not rule out the presence of acute leukemia or other genetic aberrations
- ⚠Results must be interpreted in conjunction with clinical findings, morphological evaluation, immunophenotyping, and conventional cytogenetics
- ⚠Rare or novel translocations not covered by this targeted panel will not be detected
- ⚠This test does not detect point mutations (e.g., FLT3, NPM1, CEBPA) which may also be relevant in AML classification
Risks & Considerations
- ●Minor bruising or discomfort at the blood draw site
- ●For bone marrow aspiration: localized pain, minor bleeding, or very rare risk of infection at the biopsy site
- ●Fainting or lightheadedness during or after blood draw (rare)
- ●Slight soreness at the bone marrow aspiration site for 1–2 days
Interfering Factors
- ●Prior chemotherapy may affect gene expression levels and detection sensitivity
- ●Hemolyzed or clotted blood samples may yield inaccurate or uninterpretable results
- ●Insufficient sample volume may compromise test performance
- ●Delayed sample transport without proper temperature control may degrade RNA integrity
- ●Recent blood transfusions may dilute leukemic cell population in peripheral blood
Compare With Similar Tests
| Test | Acute Leukemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) | |||
|---|---|---|---|---|
| Comparison | Acute Leukemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) |
Frequently Asked Questions
What is the Acute Leukemia Mini Panel?
What gene rearrangements does this panel detect?
Who should undergo this test?
What sample is required for this test?
Is fasting required before this test?
How long does it take to get the results?
What does a positive result mean?
What is the cost of the Acute Leukemia Mini Panel?
Is this test covered by insurance?
How accurate is the Acute Leukemia Mini Panel?
Can this test be done at home?
What is the difference between this panel and a comprehensive leukemia panel?
Related Tests
B-Cell Rearrangement Detection Test
₹22,000Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel Test
₹20,000Epstein-Barr Virus Early RNA (EBER-ISH) In-Situ-Hybridization Test
₹6,000OncoPro NCCN Lung Cancer Panel with PD-L1 Test
₹140,400Acute Myeloid Leukemia (AML) Cytogenetics Panel Test
₹23,000AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test
₹6,000Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.